Molecular buckets: Cyclodextrins for oral cancer therapy

Therapeutic Delivery

Volumn 3, Issue 1, 2012, Pages 43-57

  Calleja, Patricia ^a   Huarte, Judit ^a   Agüeros, Maite ^a   Ruiz Gatón, Luisa ^a   Espuelas, Socorro ^a   Irache, Juan M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2 HYDROXYPROPYL GAMMA CYCLODEXTRIN; 2,3 HYDROXYPROPYL BETA CYCLODEXTRIN; 2,6 DI O ETHYL BETA CYCLODEXTRIN; 2,6 DI O METHYL BETA CYCODEXTRIN; 3 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; CAVERJECT DUAL; CEFDITOREN PIVOXIL; CEPHALOSPORIN; CHLORAMPHENICOL; CISAPRIDE; CLOROCIL; CYANOACRYLATE; CYCLODEXTRIN; DICLOFENAC; GAMMA CYCLODEXTRIN; GLUCURONYL GLYCOSYL BETA CYCLODEXTRIN; GLYCOSYL BETA CYCLODEXTRIN; MALTOSYL BETA CYCLODEXTRIN; MITOMYCIN; MITOMYCIN C; NANOCARRIER; NANOPARTICLE; O CARBOXYMETHYL O ETHYL BETA CYCLODEXTRIN; PACLITAXEL; PER O ETHYL BETA CYCODEXTRIN; PER O METHYL BETA CYCODEXTRIN; PROSTAGLANDIN E1; SOLUBILIZER; SULFOBUTYLETHER BETA CYCLODEXTRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; INTESTINE MUCOSA PERMEABILITY; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84055221823     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.140     Document Type: Review

References (132)

1. Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr. Oncol. Rep. 12(4), 247-252 (2010).
2. Weingart SN, Brown E, Bach PB et al. NCCN Task Force report: oral chemotherapy. J. Natl Compr. Canc. Netw. 3, S1-S14 (2008). (Pubitemid 351497279)
3. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med. 35(12), 1505-1509 (1992).
4. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15(1), 110-115 (1997). (Pubitemid 27021524)
5. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7(8), 455-465 (2010).
6. Irshad S. MN. Considerations when choosing oral chemotherapy: identifying and responding to patient need. Eur. J. Cancer Care 19(Suppl. 1), 5-11 (2010).
7. Terwogt JM, Schellens JH, Huinink WW, Beijnen JH. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat. Rev. 25(2), 83-101 (1999). (Pubitemid 29353668)
8. Kuppens IE, Breedveld P, Beijnen JH, Schellens JH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest. 23(5), 443-464 (2005). (Pubitemid 41324362)
9. Washington N, Washington C, Wilson C. In: Physiological Pharmaceutics: Barriers to Drug Absorption. Taylor and Francis Group, London, UK (2011).
10. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40(3), 159-168 (2001). (Pubitemid 32324448)
11. Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J. Clin. Invest. 117(11), 3173-3176 (2007). (Pubitemid 350096972)
12. Cai Z, Wang Y, Zhu LJ, Liu ZQ. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr. Drug Metab. 11(2), 197-207 (2010).
13. Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond.) 5(2), 287-306 (2010).
14. Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on Pgp modulation. Drug Discov. Today 14(21-22), 1067-1074 (2009).
15. Villiers A. Sur la fermentation de la fécule par l'action du ferment butyrique. Compt. Rend. Acad. Sci. 112, 536-538 (1891).
16. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329(1-2), 1-11 (2007). (Pubitemid 44937538)
17. Szejtli J. Past, present, and future of cyclodextrin research. Pure Appl. Chem. 76(10), 1825-1845 (2004).
18. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 3(1), 1-40 (1987). (Pubitemid 17231927)
19. Albers E, Muller BW. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. 12(4), 311-337 (1995). (Pubitemid 26043670)
20. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. (Tokyo) 52(8), 900-915 (2004). (Pubitemid 41701863)
21. Szejtli J. Cyclodextrin Technology. Kluwer Academic Publisher, Dordrecht, The Netherlands (1988).
22. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85(10), 1017-1025 (1996). (Pubitemid 26338912)
23. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85(11), 1142-1169 (1996). (Pubitemid 26372882)
24. Duchene D, Wouessidjewe D. Industrial uses of cyclodextrins and their derivatives. J. Coord. Chem. 27(1-3), 223-236 (1992).
25. Thompson DO. Cyclodextrins - enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14(1), 1-104 (1997). (Pubitemid 27079973)
26. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 83(2), 367-382 (1976).
27. Debouzy JC, Fauvelle F, Crouzy S et al. Mechanism of alpha-cyclodextrin induced hemolysis. 2. A study of the factors controlling the association with serine-, ethanolamine-, and choline-phospholipids. J. Pharm. Sci. 87(1), 59-66 (1998). (Pubitemid 28079262)
28. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86(2), 147-162 (1997). (Pubitemid 27078377)
29. Singh M, Sharma R, Banerjee UC. Biotechnological applications of cyclodextrins. Biotechnol. Adv. 20(5-6), 341-359 (2002). (Pubitemid 35348280)
30. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J. Control. Release 123(2), 78-99 (2007). (Pubitemid 47566400)
31. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 36(1), 125-141 (1999). (Pubitemid 29074480)
32. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 6(2), E329-E357 (2005).
33. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413-420 (1995).
34. Yu LX, Amidon GL, Polli JE et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19(7), 921-925 (2002). (Pubitemid 34804232)
35. Loftsson T, Masson M, Brewster ME. Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. 93(5), 1091-1099 (2004). (Pubitemid 38529683)
36. Loftsson T, Magnusdottir A, Masson M, Sigurjonsdottir JF. Self-association and cyclodextrin solubilization of drugs. J. Pharm. Sci. 91(11), 2307-2316 (2002). (Pubitemid 35231194)
37. Pitha J, Hoshino T, Torreslabandeira J, Irie T. Preparation of drug-hydroxypropylcyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as co-solubilizers. Int. J. Pharm. 80(2-3), 253-258 (1992).
38. Loftsson T, Magnusdottir A, Masson M. Self association and cyclodextrin solubilization of NSAIDs. J. Incl. Phenom. Macro. 44(1-4), 213-218 (2002). (Pubitemid 38075694)
39. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3(12), 1023-1035 (2004). (Pubitemid 39642365)
40. Avdeef A, Bendels S, Tsinman O, Tsinman K, Kansy M. Solubility-excipient classification gradient maps. Pharm. Res. 24(3), 530-545 (2007). (Pubitemid 46295156)
41. Park JS, Kim CK. Solubility enhancers for oral drug delivery: can chemical structure manipulation be avoided? Am. J. Drug Deliv. 2(2), 113-130 (2004).
42. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2(2), 335-351 (2005). (Pubitemid 41130887)
43. Park K. Efficient oral delivery of paclitaxel using cyclodextrin complexes. J. Control. Release 145(1), 1 (2010).
44. Cserhati T, Forgacs E, Hollo J. Interaction of taxol and other anticancer drugs with alpha-cyclodextrin. J. Pharm. Biomed. Anal. 13(4-5), 533-541 (1995).
45. Badawy SIF, Ghorab MM, Adeyeye CM. Bioavailability of danazol-hydroxypropyl-beta-cylodextrin complex by different routes of administration. Int. J. Pharm. 145(1-2), 137-143 (1996). (Pubitemid 27062994)
46. Madan J, Dhiman N, Parmar VK et al. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemoth. Pharmacol. 65(3), 537-548 (2010).
47. Yavuz B, Bilensoy E, Vural I, Sumnu M. Alternative oral exemestane formulation: improved dissolution and permeation. Int. J. Pharm. 398(1-2), 137-145 (2010).
48. Yavuz B, Sarisozen C, Vural I, Bilensoy E, Sumnu M. An alternative cyclodextrin based formulation for oral anticancer drug exemestane: in vitro and cell culture studies. J. Control. Release 148(1), e83-84 (2010).
49. Kikuchi M, Hirayama F, Uekama K. Improvement of chemical instability of carmoful in beta-cyclodextrin solid complex by utilizing some organic acids. Chem. Pharm. Bull. (Tokyo) 35(1), 315-319 (1987). (Pubitemid 17021397)
50. Piette M, Evrard B, Frankenne F et al. Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. Eur. J. Pharm. Sci. 28(3), 189-195 (2006). (Pubitemid 43766102)
51. Nakanishi K, Nadai T, Masada M, Miyajima K. Effect of cyclodextrins on biological membrane. II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. Chem. Pharm. Bull. (Tokyo) 40(5), 1252-1256 (1992).
52. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427 (1993). (Pubitemid 23237876)
53. Fenyvesi F, Fenyvesi E, Szente L et al. Pgp inhibition by membrane cholesterol modulation. Eur. J. Pharm. Sci. 34(4-5), 236-242 (2008).
54. Ishikawa M, Yoshii H, Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci. Biotechnol. Biochem. 69(1), 246-248 (2005). (Pubitemid 40383513)
55. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl Acad. Sci. USA 99(16), 10347-10352 (2002).
56. Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of Pgp to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 297(2), 547-555 (2001). (Pubitemid 32377984)
57. Pathak SM, Musmade P, Dengle S et al. Enhanced oral absorption of saquinavir with methyl-beta-cyclodextrin-preparation and in vitro and in vivo evaluation. Eur. J. Pharm. Sci. 41(3-4), 440-451 (2010).
58. Fenyvesi F, Kiss T, Fenyvesi E et al. Randomly methylated beta-cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer. J. Pharm. Sci. 100(11), 4734-4744 (2011).
59. Munoz M, Deschenaux R, Coleman AW. Observation of microscopic patterning at the air water interface by mixtures of amphiphilic cyclodextrins: a compression isotherm and Brewster angle microscopy study. J. Phys. Org. Chem. 12(5), 364-369 (1999). (Pubitemid 129663176)
60. Bilensoy E, Dogan L, Sen M, Hincal A. Complexation behavior of antiestrogen drug tamoxifen citrate with natural and modified beta-cyclodextrins. J. Incl. Phenom. Macro. 57(1-4), 651-655 (2007).
61. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv. Drug Deliv. Rev. 36(1), 29-40 (1999).
62. Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J. Control. Release 62(1-2), 263-268 (1999). (Pubitemid 29486506)
63. Memisoglu-Bilensoy E, Vural L, Bochot A et al. Tarnoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J. Control. Release 104(3), 489-496 (2005). (Pubitemid 40724944)
64. Cryan SA, Holohan A, Donohue R, Darcy R, O'Driscoll CM. Cell transfection with polycationic cyclodextrin vectors. Eur. J. Pharm. Sci. 21(5), 625-633 (2004). (Pubitemid 38447144)
65. Bilensoy E, Hincal AA. Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin. Drug Deliv. 6(11), 1161-1173 (2009).
66. Lemos-Senna E, Wouessidjewe D, Lesieur S, Puisieux F, Courraze G, Duchene D. Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrin nanospheres. Pharm. Dev. Technol. 3(1), 85-94 (1998). (Pubitemid 28252508)
67. Wouessidjewe D, Skiba M, LeroyLechat F et al. A new concept in drug delivery based on 'skirt-shaped cyclodextrin aggregates' - present state and future prospects. Stp. Pharma. Sci. 6(1), 21-28 (1996).
68. Lemos-Senna E, Wouessidjewe D, Lesieur S, Duchene D. Preparation of amphiphilic cyclodextrin nanospheres using the emulsification solvent evaporation method. Influence of the surfactant on preparation and hydrophobic drug loading. Int. J. Pharm. 170(1), 119-128 (1998). (Pubitemid 28473252)
69. Lemos-Senna E, Wouessidjewe D, Duchene D, Lesieur S. Amphiphilic cyclodextrin nanospheres: particle solubilization and reconstitution by the action of a non-ionic detergent. Colloid. Surface. B 10(5), 291-301 (1998). (Pubitemid 28218224)
70. Memisoglu E, Bochot A, Ozalp M et al. Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm. Res. 20(1), 117-125 (2003). (Pubitemid 36152926)
71. Memisoglu E, Bochot A, Sen M, Duchene D, Hincal AA. Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic beta-cyclodextrins. Int. J. Pharm. 251(1-2), 143-153 (2003). (Pubitemid 36071469)
72. Vural I, Memisoglu-Bilensoy E, Renoir JM et al. Transcription efficiency of tamoxifen citrate-loaded beta-cyclodextrin nanoparticles. J. Drug Deliv. Sci. Technol. 15(5), 339-342 (2005). (Pubitemid 41413395)
73. Bilensoy E, Gurkaynak O, Ertan M, Sen M, Hincal AA. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J. Pharm. Sci. 97(4), 1519-1529 (2008).
74. Bilensoy E, Gurkaynak O, Dogan AL, Hincal AA. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int. J. Pharm. 347(1-2), 163-170 (2008). (Pubitemid 350180328)
75. Cirpanli Y, Bilensoy E, Dogan AL, Calis S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur. J. Pharm. Biopharm. 73(1), 82-89 (2009).
76. Cirpanli Y, Allard E, Passirani C et al. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int. J. Pharm. 403(1-2), 201-206 (2011).
77. Quaglia F, Ostacolo L, Mazzaglia A et al. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 30(3), 374-382 (2009).
78. Sortino S, Mazzaglia A, Scolaro LM et al. Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as carrier-sensitizer system in photodynamic cancer therapy. Biomaterials 27(23), 4256-4265 (2006).
79. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in p388 leukemia in vivo and in vitro through enhanced cyto-toxicity of vincristine and vinblastine by verapamil. Cancer Res. 41(5), 1967-1972 (1981). (Pubitemid 11114605)
80. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res. 4(10), 2293-2297 (1998). (Pubitemid 28477891)
81. Bardelmeijer HA, Beijnen JH, Brouwer KR et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6(11), 4416-4421 (2000).
82. Dong YC, Feng SS. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(30), 6068-6076 (2005).
83. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the Pgp inhibitor KR30031. Pharm. Res. 20(1), 24-30 (2003). (Pubitemid 36152913)
84. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliver. Rev. 34(2-3), 191-219 (1998). (Pubitemid 28535112)
85. Woodley J. Bioadhesion - new possibilities for drug administration? Clin. Pharmacokinet. 40(2), 77-84 (2001). (Pubitemid 32242791)
86. Bernkop-Schnürch A. Mucoadhesive systems in oral drug delivery. Drug Discov. Today Technol. 2(1), 83-87 (2005). (Pubitemid 40946312)
87. Florence AT, Hillery AM, Hussain N, Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles - histological and analytical evidence. J. Drug Target. 3(1), 65-70 (1995).
88. Bertholon I, Ponchel G, Labarre D, Couvreur P, Vauthier C. Bioadhesive properties of poly(alkylcyanoacrylate) nanoparticles coated with polysaccharide. J. Nanosci. Nanotechnol. 6(9-10), 3102-3109 (2006). (Pubitemid 44579988)
89. Chen J, Yang WL, Li G et al. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroentero. 10(1), 112-116 (2004). (Pubitemid 38071989)
90. Feng SS, Mei L, Anitha P, Gan CW, Zhou WY. Poly(lactide)-vitamin E derivative/ montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 30(19), 3297-3306 (2009).
91. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm. Res. 18(11), 1521-1527 (2001). (Pubitemid 33022406)
92. Arbos P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J. Control. Release 96(1), 55-65 (2004). (Pubitemid 38438489)
93. Arbos P, Campanero MA, Arnangoa MA, Renedo MJ, Irache JM. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J. Control. Release 89(1), 19-30 (2003). (Pubitemid 36412111)
94. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18(6), 788-793 (2001). (Pubitemid 32783514)
95. Montisci MJ, Dembri A, Giovannuci G et al. Gastrointestinal transit and mucoadhesion of colloidal suspensions of Lycopersicon esculentum L. and Lotus tetragonolobus lectin-PLA microsphere conjugates in rats. Pharm. Res. 18(6), 829-837 (2001). (Pubitemid 32783520)
96. Arbos P, Arangoa MA, Campanero MA, Irache JM. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles. Int. J. Pharm. 242(1-2), 129-136 (2002).
97. Salman HH, Gamazo C, Campanero MA, Irache JM. Bioadhesive mannosylated nanoparticles for oral drug delivery. J. Nanosci. Nanotechnol. 6(9-10), 3203-3209 (2006). (Pubitemid 44580001)
98. Salman HH, Gamazo C, Agueros M, Irache JM. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine 25(48), 8123-8132 (2007). (Pubitemid 350046324)
99. Llabot JM, Salman H, Millotti G et al. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan. J. Microencapsul. 28(5), 455-463 (2011).
100. Agueros M, Areses P, Campanero MA et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur. J. Pharm. Sci. 37(3-4), 231-240 (2009).
101. Areses P, Agüeros MT, Quincoces G et al. Molecular imaging techniques to study the biodistribution of orally administered 99mTc-labelled naive and ligand-tagged nanoparticles. Mol. Imaging Biol. 13(6),1215-1223 (2011).
102. Agueros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J. Control. Release 145(1), 2-8 (2010).
103. Sparano JA, Wang ML, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl. J. Med. 358(16), 1663-1671 (2008). (Pubitemid 351549913)
104. Montana M, Ducros C, Verhaeghe P et al. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J. Chemother. 23(2), 59-66 (2011).
105. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl. J. Med. 355(24), 2542-2550 (2006). (Pubitemid 44917502)
106. Zhan M, Tao WY, Pan SH, Sun XY, Jiang HC. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drug. 20(5), 355-363 (2009).
107. Dhanikula AB, Panchagnula R. Localized paclitaxel delivery. Int. J. Pharm. 183(2), 85-100 (1999). (Pubitemid 29257954)
108. da Silveira AM, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res. 15(7), 1051-1055 (1998). (Pubitemid 28356922)
109. Agueros M, Ruiz-Gaton L, Vauthier C et al. Combined hydroxypropyl-beta- cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur. J. Pharm. Sci. 38(4), 405-413 (2009).
110. Calvo J, Lavandera J, Agüeros M, Irache J. Cyclodextrin/ poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. Biomed. Microdevices 13(6), 1015-1025 (2011).
111. Mooguee M, Omidi Y, Davaran S. Synthesis and in vitro release of adriamycin from star-shaped poly(lactide-co-glycolide) nano- and microparticles. J. Pharm. Sci. 99(8), 3389-3397 (2010).
112. Wang TW, Zhang CL, Liang XJ, Liang W, Wu Y. Hydroxypropyl-beta- cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system. J. Pharm. Sci. 100(3), 1067-1079 (2011).
113. McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. J. Drug Target. 2(5), 449-454 (1994).
114. Wang X, Deng L, Cai L et al. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β- cyclodextrin in liposome. J. Pharm. Sci. 100(8), 3357-3364 (2011).
115. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of Pgp and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm. Res. 21(4), 625-634 (2004). (Pubitemid 38457285)
116. Uekama K. Pharmaceutical application of cyclodextrins as multi-functional drug carriers. Yakugaku Zasshi 124(12), 909-935 (2004). (Pubitemid 41359094)
117. Bellanger N, Perly B. NMR investigations of the conformation of new cyclodextrin-based amphiphilic transporters for hydrophobic drugs - molecular lollipops. J. Mol. Struct. 273, 215-226 (1992).
118. Dodziuk H, Chmurski K, Jurczak J et al. A dynamic NMR study of self-inclusion of a pendant group in amphiphilic 6-thiophenyl- 6-deoxycyclodextrins. J. Mol. Struct. 519, 33-36 (2000). (Pubitemid 30139793)
119. Kawabata Y, Matsumoto M, Tanaka M et al. Formation and deposition of monolayers of amphiphilic beta-cyclodextrin derivatives. Chem. Lett. 11, 1933-1934 (1986).
120. Liu FY, Kildsig DO, Mitra AK. Complexation of 6-acyl-O-beta-cyclodextrin derivatives with steroids - effects of chain-length and substitution degree. Drug Dev. Ind. Pharm. 18(15), 1599-1612 (1992).
121. Zhang P, Ling CC, Coleman AW, Parrotlopez H, Galons H. Formation of amphiphilic cyclodextrins via hydrophobic esterification at the secondary hydroxyl face. Tetrahedron Lett. 32(24), 2769-2770 (1991).
122. Zhang P, Parrotlopez H, Tchoreloff P et al. Self-organizing systems based on amphiphilic cyclodextrin diesters. J. Phys. Org. Chem. 5(8), 518-528 (1992).
123. Lesieur S, Charon D, Lesieur P et al. Phase behavior of fully hydrated DMPC-amphiphilic cyclodextrin systems. Chem. Phys. Lipids 106(2), 127-144 (2000). (Pubitemid 30621439)
124. Canceill J, Jullien L, Lacombe L, Lehn JM. Channel-type molecular-structures. 2. synthesis of bouquet-shaped molecules based on a beta-cyclodextrin core. Helv. Chim. Acta 75(3), 791-812 (1992).
125. Wenz G. Synthesis and characterization of some lipophilic per(2,6-di-O-alkyl) cyclomalto-oligosaccharides. Carbohyd. Res. 214(2), 257-265 (1991). (Pubitemid 21726102)
126. Auzely-Velty R, Djedaini-Pilard F, Desert S, Perly B, Zemb T. Micellization of hydrophobically modified cyclodextrins. 1. Micellar structure. Langmuir 16(8), 3727-3734 (2000).
127. Mazzaglia A, Angelini N, Darcy R et al. Novel heterotopic colloids of anionic porphyrins entangled in cationic amphiphilic cyclodextrins: spectroscopic investigation and intracellular delivery. Chem. Eur. J. 9(23), 5762-5769 (2003).
128. Matsumoto M, Matsuzawa Y, Noguchi S, Sakai H, Abe M. Structure of hybrid Langmuir-Blodgett films of amphiphilic cyclodextrin and water-soluble azobenzene. Mol. Cryst. Liq. Cryst. 425(475-482 (2004). (Pubitemid 41270366)
129. Dubes A, Bouchu D, Lamartine R, Parrot-Lopez H. An efficient regio-specific synthetic route to multiply substituted acyl-sulphated beta-cyclodextrins. Tetrahedron Lett. 42(52), 9147-9151 (2001). (Pubitemid 33152873)
130. Granger CE, Felix CP, Parrot-Lopez HP, Langlois BR. Fluorine containing beta-cyclodextrin: a new class of amphiphilic carriers. Tetrahedron Lett. 41(48), 9257-9260 (2000).
131. Peroche S, Degobert G, Putaux JL et al. Synthesis and characterisation of novel nanospheres made from amphiphilic perfluoroalkylthio-beta-cyclodextrins. Eur. J. Pharm. Biopharm. 60(1), 123-131 (2005). (Pubitemid 40545868)
132. Skiba M, Skiba-Lahiani M, Arnaud P. Design of nanocapsules based on novel fluorophilic cyclodextrin derivatives and their potential role in oxygen delivery. J. Incl. Phenom. Macro. 44(1-4), 151-154 (2002). (Pubitemid 38075681)